SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Biotech Showcase 2016 conference on Monday, January 11, 2016 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner, Stern Investor Relations, Inc. 212.362.1200, [email protected]
